Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
Shares of Sarepta Therapeutics (NASDAQ: SRPT) nosedived last week as the Food and Drug Administration (FDA) did not approve the company's gene therapy treatment, SRP-9001. Should investors be worried about this development, or is this just a bump in the road for the biotech stock? Investors were expecting a decision on Sarepta's gene therapy SRP-9001 this week.